Revenues were $250 K with a net loss of $17.8 M or $0.03 per 770.5 M fully-diluted shares outstanding. ACTC.OB recognized $51.5 K and $37.5 K in license fee revenue.
Revenues were $1.7 M with a net loss of $2.6 M or $0.14 per share. Q1/10 revenue was $1.7 M, due principally to contract revenues in connection with the collaboration with Pfizer. R&D expenses of $2.8 M reflected increases in personnel costs, sponsored research while other R&D expenses, patent legal fees were partially offset by decreases Read more…
Revenues were $4.764 M. The net loss for Q3/10 was $1.365 M or $0.02 per share. For Q3/10, total revenues of $4.8 M (versus $6 M million in Q2/10). For Q3/10, KOOL reported total revenues of $4.8 M versus $6 M in Q2/10; recording disposable revenues of $3 M in Q3/10 versus $3.5 M in Q2/10. Read more…
Physician scientists at the Texas Heart Institute at St. Luke’s Episcopal Hospital (THI at St. Luke’s) have been awarded a grant of almost $1.5 M by the NIH for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments. Read more…
Q1/10 earnings fell 84 % but, posted a profit of $2.4 M, or $0.07 per diluted common shares, versus a profit of $14.8 M, or a $0.24 loss per share, in Q1/09. Q1/10 revenue fell 10 % to $11.3 M coming from the Genzyme Corp agreement licensing fee and a $1 M milestone payment from a venture with JCR Pharmaceuticals. Read more…
CYTX (5/7/10) reported that stem and regenerative cells derived from adipose tissue (ADRCs) improved patient outcomes in two (2) EU clinical studies, 1 in acute heart attacks and the other in chronic heart disease. Both studies incorporated CYTX’s proprietary cell processing device, the Celution® System, as the means to separate, concentrate and prepare each patient’s own cells for re-injection in the same procedure. Read more…
The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump. Read more…
The 1st clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption (MVO2) and patients’ aerobic capacity measured as metabolic equivalents (METS); and reduced the extent of infarct size in the left ventricle. Stem and regenerative cells were prepared and made available at the point-of-care using the Celution(R) System, the proprietary cell processing device developed by trial sponsor CYTX. Read more…
Investor conference call will present an update on clinical development efforts related to critical limb ischemia (CLI) on Monday, May 10, 2010 @ 1:00 pm (ET). The event will also feature a Q&A session with Anthony J. Comerota, MD, FACS, FACC, director of the Jobst Vascular Center in Toledo, Ohio. Read more…
OSIR announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn’s disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population. Additionally, the analysis showed that Prochymal continued to demonstrate a benign safety profile with no significant differences in any of the pre-defined safety outcomes compared to placebo. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.